- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02182570
WAL 801 CL Dry Syrup in Pediatric Atopic Dermatitis Patients
July 11, 2014 updated by: Boehringer Ingelheim
Phase III Open-labeled Study of WAL 801 CL Dry Syrup in Pediatric Atopic Dermatitis Patients
The safety and efficacy of WAL 801 CL (epinastine hydrochloride) Dry Syrup in the treatment of atopic dermatitis in children was evaluated and plasma drug concentrations were measured.
Study Overview
Study Type
Interventional
Enrollment (Actual)
62
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 15 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
For inclusion in this study, subjects must be pediatric atopic dermatitis patients that meet the following criteria and thus be appropriate for observation of pruritus. Diagnosis of atopic dermatitis will be conducted in accordance with the "Definition and Diagnostic Criteria of Atopic Dermatitis", issued by the Japanese Dermatological Association.
- 15 years of age or younger
- Body weight of 14 kg or more
- Outpatients
- The patient has been undergoing treatment with a "very strong" or lower-grade external steroid preparation for >= 1 week at the time informed consent is obtained
- Pruritus with "2" or higher grade at the start time of administration
Exclusion Criteria:
- Use of sustained release adrenocorticotropic hormone (Kenacort® A, Depo-medrol®, etc.), oral preparation of methotrexate, or oral preparation of ciclosporin, within 4 weeks before initial administration of the investigational product
- Oral intake, inhalation and injection of any steroid within 2 weeks before initial administration of the investigational product
- Use of any external steroid preparation at "Strongest" in any sites other than the face or scalp within 2 weeks before initial administration of the investigational product
- Undergoing phototherapy
- Undergoing specific desensitization therapy or modulation therapy
- Past history of contact dermatitis caused by external steroid preparation
- Possibility of exacerbation by an external steroid preparation of infectious skin disease caused by bacteria, fungi, or virus
- Clinically significant hepatic, renal, or cardiac disease or other complications: therefore, judgement that the patient was ineligible for inclusion in this study. Patients must be excluded from the study if the patients fell under Grade 2 or more, in the MHW (Ministry of health and welfare) Adverse Reaction Severity Classification Criteria
- Past history of allergy to any drug
- Participation in any other clinical study, or history of participation in any other clinical study within 6 months before the date when the patient gave consent to participate in this study
- Judgement by the Principal Investigator or Investigator that the patient is ineligible for inclusion in this study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: WAL 801 CL
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall incidence of adverse events
Time Frame: up to 12 weeks
|
up to 12 weeks
|
Occurrence of abnormal changes in laboratory measurements (haematological tests, blood biochemical tests, and urinalysis)
Time Frame: Baseline, weeks 4, 8 and 12
|
Baseline, weeks 4, 8 and 12
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Degree of pruritus
Time Frame: at weeks 4, 8 and 12
|
at weeks 4, 8 and 12
|
Degree of rash
Time Frame: at weeks 4, 8 and 12
|
at weeks 4, 8 and 12
|
Pruritus score obtained through the itching questionnaire
Time Frame: at weeks 4, 8 and 12
|
at weeks 4, 8 and 12
|
Impression on pruritus of the patient or the parent
Time Frame: week 12
|
week 12
|
Plasma concentration of epinastine hydrochloride
Time Frame: pre-dose and 6, 12, 18, 24, 30, 36 hours post-dose
|
pre-dose and 6, 12, 18, 24, 30, 36 hours post-dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2001
Primary Completion (Actual)
February 1, 2002
Study Registration Dates
First Submitted
July 2, 2014
First Submitted That Met QC Criteria
July 2, 2014
First Posted (Estimate)
July 8, 2014
Study Record Updates
Last Update Posted (Estimate)
July 14, 2014
Last Update Submitted That Met QC Criteria
July 11, 2014
Last Verified
July 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Immune System Diseases
- Hypersensitivity, Immediate
- Genetic Diseases, Inborn
- Skin Diseases, Genetic
- Hypersensitivity
- Skin Diseases, Eczematous
- Dermatitis
- Dermatitis, Atopic
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Histamine H1 Antagonists
- Histamine Antagonists
- Histamine Agents
- Epinastine
Other Study ID Numbers
- 262.260
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dermatitis, Atopic
-
Catalysis SLCompletedAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related Conditions | Atopic Dermatitis \(AD\)Serbia
-
Jacob Pontoppidan ThyssenThe Novo Nordic FoundationRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis FlareDenmark
-
ShaperonNot yet recruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis of Scalp
-
University of California, San FranciscoSanofi; Regeneron PharmaceuticalsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related ConditionsUnited States
-
PfizerActive, not recruitingEczema | Atopic Dermatitis | Eczema, Atopic | Atopic Dermatitis, UnspecifiedUnited States, Canada, Czechia, Poland
-
AmgenCompletedDermatitis, Atopic DermatitisCanada, United States, Japan
-
Hadassah Medical OrganizationUnknownATOPIC DERMATITIS
-
SanofiCompletedAtopic Dermatitis | Dermatitis AtopicChina
-
SanofiCompletedDermatitis AtopicSaudi Arabia, Kuwait, United Arab Emirates
-
National Institute of Allergy and Infectious Diseases...Atopic Dermatitis Research NetworkCompletedAtopic Dermatitis (AD) | Non-atopic Healthy ControlsUnited States
Clinical Trials on WAL 801 CL dry syrup
-
Boehringer IngelheimCompletedDermatitis, Atopic
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompletedRhinitis, Allergic, Perennial
-
SamA Pharmaceutical Co., LtdCompletedPerennial Allergic RhinitisKorea, Republic of
-
Shlomo Melmed, MDNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Terminated
-
UCB Biopharma SRLRecruitingHealthy Study ParticipantsJapan
-
PT BernofarmPT Pharma Metric LabsCompleted
-
UCB Biopharma S.P.R.L.CompletedHealthy VolunteersUnited Kingdom
-
TakedaCompleted
-
GlaxoSmithKlineCompletedRhinitis, Allergic, Perennial